Most Recent
English indie band The xx has lost its bid to block an Australian sunglasses company co-founded by former AFL player Tom Sheridan from registering its 'xx' trade mark, with a delegate from the Trade Marks Office finding the band's reputation did not extend to clothing or eyewear.
A judge has denied an application by industrial filter manufacturer Laminar Air Flow to add a new respondent in a long-running trade mark dispute against rival Vokes Ltd, with a judge finding the company had provided no explanation as to why the bid was made just four months before trial.
A dispute over approximately $466,000 in unpaid legal costs has been sent to the Victorian Supreme Court after DLA Piper admitted it breached its disclosure obligations to a client in a patent case over a laser safety system.
Beer giant Lion has slapped a WA retailer with a trade mark lawsuit over an offensive t-shirt that features the mark for its Emu Export beer with the words "wife basher" emblazoned across the top.
A judge has granted a request by Otsuka and Bristol-Myers Squibbs to withdraw admissions in proceedings brought by Generic Health seeking damages, after the generic drug maker was temporarily blocked from selling a generic version of antipsychotic Abilify in a patent dispute in which it ultimately triumphed.
The company behind the ubiquitous bubble wrap has won a consumer case against Visy Packaging, with the Federal Court awarding almost $3 million in damages after finding a spoon-lid combination supplied to yoghurt maker Chobani breached an exclusive licence agreement.
Pharmaceutical company Generic Health has told the Federal Court that, on advice from their solicitors, Otsuka and Bristol-Myers Squibb "deliberately" chose not to disclose their reasons for an admission in a long-running patent case over the anti-psychotic drug Abilify, which they are now seeking to withdraw.
Otsuka Pharmaceuticals and Bristol Myers-Squibb are seeking to withdraw admissions in patent litigation against Generic Health over anti-psychotic drug Abilify, following a landmark ruling last year against Wyeth that clarified the issue of compensation under the usual undertaking for damages in pharmaceutical patent cases.
US biotechnology company ICOS has settled a dispute with Australian-based Arrow Pharma over the patents for erectile dysfunction drug Cialis, less than 12 months after a court upheld the validity of the patents in a separate case.
IP Australia has ordered biotech firm MacroGenics to amend its patent for a type of polypeptide used in treatments for cancer, autoimmune disorders and other diseases after a successful opposition from the chairman of intellectual property boutique Wrays.